Prolocor is developing the pFCG precision diagnostic test, which quantifies FcγRIIa expression on the surface of platelets to help assess thrombosis risk and guide individualized treatment decisions for cardiovascular disease, including heart attack and stroke
Prolocor is developing the pFCG precision diagnostic test, which quantifies FcγRIIa expression on the surface of platelets to help assess thrombosis risk and guide individualized treatment decisions for cardiovascular disease, including heart attack and stroke.